Infliximab is the first-line agent of choice for pustular psoriasis, dermatologists suggest, but ustekinumab is a good…
Read more
People with psoriasis have an increased risk of developing and dying from a variety of cancers, particularly if their skin…
Read more
People with psoriasis have an increased risk of inflammatory bowel disease and vice versa, a study shows. Danish…
Read more
Biologic therapies — particularly tumor necrosis factor inhibitors — are associated with increases in weight and BMI in…
Read more
The anti-interleukin-23 monoclonal antibody risankizumab is more effective for treating plaque psoriasis than the TNF-alpha…
Read more
Patients with severe psoriasis are seven times more likely to have advanced liver fibrosis than the general population,…
Read more
Patients with psoriasis who start treatment with apremilast, etanercept or ustekinumab have a lower risk of developing a…
Read more